Mandate

Vinge has advised Egetis Therapeutics in connection with a combined financing comprising an equity private placement and debt financing

Vinge has advised Egetis Therapeutics AB (publ) (“Egetis Therapeutics”), an innovative and integrated pharmaceutical company focusing on projects in late-stage development for commercialization for treatments of serious diseases with significant unmet medical needs in the orphan drug segment, listed on Nasdaq Stockholm, in connection with a combined financing comprising a SEK 172 million equity private placement and a SEK 290 million debt financing.

Vinge’s team consisted of Dain Hård Nevonen, Amanda Knutsson, Lorin Arabi and Isabell Bitar (Capital Markets and Public M&A) and of Albert Wållgren, Arvid Weimers and Ida Redander (Banking and finance).

Related

Vinge advises Sobro on its investment in Västkustens Konstruktionsbyrå

Västkustens Konstruktionsbyrå has decided to broaden its ownership structure by bringing in Sobro as a new co-partner and majority shareholder. The founders will remain with the company as the CEO and CTO respectively, and as significant shareholders. Västkustens Konstruktionsbyrå is an engineering consultancy company based in Gothenburg with cutting-edge expertise in project management, civil engineering and design.
April 23, 2026

Vinge has advised Egetis Therapeutics in connection with a directed share issue

Vinge has advised Egetis Therapeutics AB (publ) (“Egetis Therapeutics”), listed on Nasdaq Stockholm, in connection with a directed share issue whereby Egetis Therapeutics raised proceeds of SEK 350 million before transaction costs.
April 22, 2026

Vinge has advised Alder on the establishment of Alder Strategic Opportunities Fund I and on a fund credit facility agreement in connection with the fundraising

Vinge has advised Alder on the establishment of the continuation fund Alder Strategic Opportunities Fund I AB. In connection with the establishment, the fund acquires the portfolio companies SI and SMG from Alder II. Vinge also advised Alder on the entering into of a fund credit facility agreement with SEB.
April 20, 2026